All News
Proposed Cancer Screening for Inflammatory Myositis Patients
Today's plenary session features a novel proposal on how and which patients with Idiopathic Inflammatory Myopathy (IIM) should be screened for cancer. Abstract 0002 by Oldroyd et al, entitled "Cancer Screening Recommendations for Patients with Idiopathic Inflammatory Myopathy" took on this thorny practice issue.
Read Article
Christ et al. 1 year follow up of GUSTO - tocilizumab monotherapy in GCA after 3 days only of steroid. Week 52 - 13/18 in relapse free remission. Week 104 12/18 in relapse free remission @rheumnow #ACR22 Abstr#0470 #ACRbest https://t.co/Pnvoeqb8rp https://t.co/dB6F25Krgg
Richard Conway RichardPAConway ( View Tweet)
Gomez et al. RA patient derived ACPAs both prevent and ameliorate collagen-antibody induced arthritis when given at early but not late stage in an animal model. Appears to be mediated through NETs @rheumnow #ACR22 Abstr#0045 https://t.co/HSD0oZBaha https://t.co/OqTv4XLXws
Richard Conway RichardPAConway ( View Tweet)
Bui et al. Screening for ANCA in ILD. Present in 9.8% . 65.4% of these had AAV. No difference in pulmonary outcomes. More steroids, immunosuppressives, hospitalisations. @rheumnow #ACR22 Abstr#0438 https://t.co/RGdnDWSpNF https://t.co/xYeCUoTqqy
Richard Conway RichardPAConway ( View Tweet)
Endothelin-1, pro-inflammatory protein involved in multiple vascular and fibrosing abnormalities, may be a biomarker for differentiating between IPF and IIM-ILD or SSc-ILD. I'm always interested in potential biomarkers for clinic! Abs 0123 #ACR22 @RheumNow https://t.co/I69X4V0Zoa
Dr. Rachel Tate uptoTate ( View Tweet)
BIOBADASER cohort showing risk of incident cancer in rheumatic disease and previous malignancy was not difference between TNFi and other biologics/tsDMARDs. Need bigger numbers (esp with JAKi) to really reassure.
@RheumNow ABST0267 #ACR22 #ACRBest
https://t.co/0YutuCBOb8 https://t.co/btYrCA6UDh
Julian Segan JulianSegan ( View Tweet)
#abst037 #acr22 @rheumnow REGISPONSER & RESPONDIA study of 231 pts w/late- vs early-onset PsA: late-onset> often male , ⬆️structural damage, ⬆️ FASFI, ⬆️ UE arthritis. Sacroiliitis& enthesitis ⬇️ frequent in late-onset. No effect on quality of life, dis activity & Rx choice https://t.co/IPRc1r2sxZ
Olga Petryna DrPetryna ( View Tweet)
How do we decide which RA patients are best for #telehealth?
Abstract #1291, Ignite session
🖥@DavidLeverenz et. al created a predictive model to answer this question
🖥Patient age, diagnosis, medications, and RAPID3 score impacted the model
@RheumNow #ACR22 https://t.co/JztTbQ4zfZ
Catherine Sims, MD DrCassySims ( View Tweet)
Leung et al @drceowen @drdavidliew persistence of fatigue, sleep and mood disorders in treated PMR patients in clinical remission. higher PSQI (lower quality sleep), higher BRAF (fatigue), higher HAD (depression, anxiety) @rheumnow #ACR22 Abstr#0204 https://t.co/zoeBNO6vVD https://t.co/TGC57kj6of
Richard Conway RichardPAConway ( View Tweet)
RTX vs CYCLO for CTD ILD
🌟RECITAL trial🌟
🫁Best ⬆️ in lung fn seen in IIM + MCTD assoc ILD for both agents
🫁SSc-ILD- lung function stabilisation only (no ⬆️)
👉 In SSc RTX improved skin thickness (mRss 24wks)
⬇️ a/e RTX
#ACR22 @RheumNow
Abst#0003 #plenary https://t.co/XdaaSFfxSP
Patricia Harkins DrTrishHarkins ( View Tweet)
Question is: does early stage PNL protect vs vascular remodelling in GCA? What about TCZ?
Salvarini group:
18 new GCA pts
GUSTO Rx (TCZ +IVMPx3, no ongoing PNL)
PET/CT: 0, 24, 52w
inflamm controlled but aortic diltation
plausible concerns reinforced!
ABST0480 #ACR22 @RheumNow https://t.co/Wnw4oxaZn7
David Liew drdavidliew ( View Tweet)
RECITAL trial #CTD with #ILD RCT of #rituximab vs #cyclophosphamide showed value overall with each Rx. Only 6 months as then maybe you would retreat w rituximab? Not superior on lungs but in #scleroderma-skin improvement better w RTX. #ACRBest #ACR22 @RheumNow abst#3 Impt for Rx https://t.co/lX1YPsr5U6
Janet Pope Janetbirdope ( View Tweet)
I implemented a Fast Track GCA clinic at my hospital (>60 encounters now!)
I have have begun to think the main benefit is ACCESS
Ultrasound is great and I do them, but I recommend starting one REGARDLESS of whether or not you do ultrasound
#ACR22 @RheumNow #0463 https://t.co/4uuotmNnoi
Mike Putman EBRheum ( View Tweet)
#ACR2022 Abstr#0003. Subgroup analysis from RECITAL RCT Rituximab vs Cyclophosphamide in CTD-ILD showed both therapies improved FVC in Myositis and MCTD but not Scleroderma. To interpret with caution (non-powered). Key message: To consider RTX as option for CTD-ILD @RheumNow https://t.co/NhJKXRdw7q
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#acr22 #abst0003 @RheumNow RECITAL: RTX vs CYC for CTD related ILD:comparable in MCTD, CYC better for myositis related ILD. Both stabilize but not improve FVC in SSc ILD. In SSc RTX but not CYC improved skin thickness by mRss at 24 wks. better safety of RTX vs CYC #acrbest https://t.co/6Hry5hy1SS
Olga Petryna DrPetryna ( View Tweet)
What were the most common adverse events in @pfizer funded Xeljanz for AS?
💩diarrhea
😴fatigue
🧠headache
🫀hypertension
📍weight gain
#ACR22 @RheumNow
Catherine Sims, MD DrCassySims ( View Tweet)
@vitortexas @RheumNow Observational data, no doubt some channelling! This data is not definitive, but highlights serious questions.
Our practices need to be challenged - IVMP has questionable biological plausibility, never had clear benefit, but has clear harm.
Thanks for the comment! #ACR22
David Liew drdavidliew ( View Tweet)
Association between RA and coeliac disease: CD pts = 57% higher risk of RA vs. matched non-CD pts. Risk associated w/ age aOR 2, female aOR 2.6, socioeconomic status aOR 1.2, Medicaid aOR : 1.3.
https://t.co/APdWW7f1U6
Abst #0271 #ACR22 @Rheumnow https://t.co/djriO3QMAh
Aurelie Najm AurelieRheumo ( View Tweet)
Neural networks can delineate different forms of inflammatory arthritis (sero+, sero- & PsA) based on structural/inflammation patterns on MRI. Required use of contrast enhancement.
Are we going to be obsolete soon @DrCMcMaster?
@RheumNow ABSR0242 #ACR22
https://t.co/JExk9HiIYu https://t.co/G2tCafE8A7
Julian Segan JulianSegan ( View Tweet)
#ACR22 Abstr#0004 Macrophage Activation Syndrome is associated with Systemic JIA #arthritis but how do they link up? Mice studies show mTORC1 is a key driver. Studies needed to assess mTORC1-inhibitor e.g. rapamycin, sirolimus etc. for SJIA-related MAS @RheumNow https://t.co/sH9seK1n8u
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)